TERT Expression in Pituitary Adenomas

Celik, Mehmet; YALTA, Tülin Deniz; GÜLDİKEN, Sibel; SARIKAŞ, Nurtaç; ÖZYILMAZ, Filiz; KUTLU, ALİ KEMAL; Süt, Necdet; ÖZ PUYAN, FULYA; CAN, NURAY; Yılmaz Bülbül, Buket; ayturk, semra

2 0

Yıl: 2017 Cilt: 33 Sayı: 2 Sayfa Aralığı: 103 - 111 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

TERT Expression in Pituitary Adenomas

Öz:

Objective: Although pituitary adenomas have benign histomorphological features, some of them may present in an aggressive manner. To predict the behaviour of these tumours, telomerase reverse transcriptase (TErT) activity in pituitary adenomas has been the subject of a few studies with contradictory results. This study aims to investigate whether immunohistochemical expression of TErT differs in neoplastic and nonneoplastic pituitary tissues and aims to investigate whether TErT expression is related to clinicopathological features of pituitary adenomas.Material and Method: The study included 48 patients who had been diagnosed with pituitary adenomas and had clinical follow-ups. nonneoplastic pituitary tissues were obtained from autopsy specimens (n=20). Immunohistochemistry for TErT antibody was performed. Both the nuclear and cytoplasmic expression of TErT antibody was noted, and total combined TErT staining was evaluated according to nuclear and cytoplasmic stainings. Results: TErT expression did not differ between neoplastic and nonneoplastic pituitary tissues. neither total (combined nuclear and cytoplasmic) TErT nor nuclear TErT expression revealed any statistically significant relationship with any of the clinicopathological features. Higher cytoplasmic TErT expression was observed in adenomas with recurrence than adenomas without recurrence (p=0.035).Conclusion: This study introduces the notion that immunohistochemical expression of TErT does not differ in neoplastic and nonneoplastic pituitary tissues. Pituitary adenomas with cytoplasmic immunohistochemical expression of TErT have significantly higher rates of recurrence. Further studies, including combined methods of immunohistochemistry and molecular analyses in larger groups, may reveal applicable results for the clinical significance of TErT in pituitary adenomas.

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Mete O, Ezzat S, Asa SL. Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol. 2012;49:R69-78.
2. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE. The prevalence of pituitary adenomas: A systematic review. Cancer. 2004;101:613-9.
3. Ortiz-Plata A, Tena Suck ML, Lopez-Gomez M, Heras A, Sanchez Garcia A. Study of the telomerase hTERT fraction, PCNA and CD34 expression on pituitary adenomas. Association with clinical and demographic characteristics. J Neurooncol. 2007;84:159-66.
4. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fevre-Montange M, Rey C, Figarella-Baranger D, Raverot G, Belin MF, Lachuer J, Trouillas J. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer. 2007;14:887- 900.
5. DeLellis RA. Pathology and genetics of tumours of endocrine organs. Lyon:IARC Press; 2004.
6. Mete O, Asa SL. Clinicopathological correlations in pituitary adenomas. Brain Pathol. 2012;22:443-53.
7. Gomez-Hernandez K, Ezzat S, Asa SL, Mete O. Clinical implications of accurate subtyping of pituitary adenomas: Perspectives from the treating physician. Turk Patoloji Derg. 2015;31 Suppl 1:4-17.
8. Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg. 1986;65:733-44.
9. Wierinckx A, Raverot G, Nazaret N, Jouanneau E, Auger C, Lachuer J, Trouillas J. Proliferation markers of human pituitary tumors: Contribution of a genome-wide transcriptome approach. Mol Cell Endocrinol. 2010;326:30-9.
10. Wierinckx A, Roche M, Raverot G, Legras-Lachuer C, Croze S, Nazaret N, Rey C, Auger C, Jouanneau E, Chanson P, Trouillas J, Lachuer J. Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. Brain Pathol. 2011;21:533-43.
11. Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prevot V, Lassalle P, Trouillas J, Delehedde M, Maurage CA. Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol. 2012;22:757-64.
12. Mete O, Hayhurst C, Alahmadi H, Monsalves E, Gucer H, Gentili F, Ezzat S, Asa SL, Zadeh G. The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas. Endocr Pathol. 2013;24:191-8.
13. De Martino I, Visone R, Wierinckx A, Palmieri D, Ferraro A, Cappabianca P, Chiappetta G, Forzati F, Lombardi G, Colao A, Trouillas J, Fedele M, Fusco A. HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res. 2009;69:1844-50.
14. Martins CS, Santana-Lemos BA, Saggioro FP, Neder L, Machado HR, Moreira AC, Calado RT, de Castro M . Telomere length and telomerase expression in pituitary tumors. J Endocrinol Invest. 2015;38:1243-6.
15. Martinez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer. 2011;11:161-76.
16. Kochling M, Ewelt C, Furtjes G, Peetz-Dienhart S, Koos B, Hasselblatt M, Paulus W, Stummer W, Brokinkel B. hTERT promoter methylation in pituitary adenomas. Brain Tumor Pathol. 2016;33:27-34.
17. Xu L, Li S, Stohr BA. The role of telomere biology in cancer. Annu Rev Pathol. 2013;8:49-78.
18. Agostini A, Panagopoulos I, Andersen HK, Johannesen LE, Davidson B, Trope CG, Heim S, Micci F. HMGA2 expression pattern and TERT mutations in tumors of the vulva. Oncol Rep. 2015;33:2675-80.
19. Vallarelli AF, Rachakonda PS, Andre J, Heidenreich B, Riffaud L, Bensussan A, Kumar R, Dumaz N. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation. Oncotarget. 2016;7:53127-36.
20. Chen C, Han S, Meng L, Li Z, Zhang X, Wu A. TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas. PLoS One. 2014;9:e100297.
21. Martins CS, de Castro M, Calado RT. Absence of TERT promoter mutations in pituitary adenomas. J Endocrinol Invest. 2016;39:933-4.
22. Kyo S, Masutomi K, Maida Y, Kanaya T, Yatabe N, Nakamura M, Tanaka M, Takarada M, Sugawara I, Murakami S, Taira T, Inoue M. Significance of immunological detection of human telomerase reverse transcriptase: Re-evaluation of expression and localization of human telomerase reverse transcriptase. Am J Pathol. 2003;163:859-67.
23. Yoshino A, Katayama Y, Fukushima T, Watanabe T, Komine C, Yokoyama T, Kusama K, Moro I. Telomerase activity in pituitary adenomas: Significance of telomerase expression in predicting pituitary adenoma recurrence. J Neurooncol. 2003;63:155-62.
24. Harada K, Arita K, Kurisu K, Tahara H. Telomerase activity and the expression of telomerase components in pituitary adenoma with malignant transformation. Surg Neurol. 2000;53:267-74.
25. Hiraga S, Ohnishi T, Izumoto S, Miyahara E, Kanemura Y, Matsumura H, Arita N. Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res. 1998;58:2117-25.
26. Lee HJ, Choi JH, Jung J, Kim JK, Lee SS, Kim GJ. Changes in PTTG1 by human TERT gene expression modulate the selfrenewal of placenta-derived mesenchymal stem cells. Cell Tissue Res. 2014;357:145-57

APA	CAN N, Celik M, Yılmaz Bülbül B, Süt N, ÖZYILMAZ F, ayturk s, GÜLDİKEN S, SARIKAŞ N, ÖZ PUYAN F, YALTA T, KUTLU A (2017). TERT Expression in Pituitary Adenomas. , 103 - 111.
Chicago	CAN NURAY,Celik Mehmet,Yılmaz Bülbül Buket,Süt Necdet,ÖZYILMAZ Filiz,ayturk semra,GÜLDİKEN Sibel,SARIKAŞ Nurtaç,ÖZ PUYAN FULYA,YALTA Tülin Deniz,KUTLU ALİ KEMAL TERT Expression in Pituitary Adenomas. (2017): 103 - 111.
MLA	CAN NURAY,Celik Mehmet,Yılmaz Bülbül Buket,Süt Necdet,ÖZYILMAZ Filiz,ayturk semra,GÜLDİKEN Sibel,SARIKAŞ Nurtaç,ÖZ PUYAN FULYA,YALTA Tülin Deniz,KUTLU ALİ KEMAL TERT Expression in Pituitary Adenomas. , 2017, ss.103 - 111.
AMA	CAN N,Celik M,Yılmaz Bülbül B,Süt N,ÖZYILMAZ F,ayturk s,GÜLDİKEN S,SARIKAŞ N,ÖZ PUYAN F,YALTA T,KUTLU A TERT Expression in Pituitary Adenomas. . 2017; 103 - 111.
Vancouver	CAN N,Celik M,Yılmaz Bülbül B,Süt N,ÖZYILMAZ F,ayturk s,GÜLDİKEN S,SARIKAŞ N,ÖZ PUYAN F,YALTA T,KUTLU A TERT Expression in Pituitary Adenomas. . 2017; 103 - 111.
IEEE	CAN N,Celik M,Yılmaz Bülbül B,Süt N,ÖZYILMAZ F,ayturk s,GÜLDİKEN S,SARIKAŞ N,ÖZ PUYAN F,YALTA T,KUTLU A "TERT Expression in Pituitary Adenomas." , ss.103 - 111, 2017.
ISNAD	CAN, NURAY vd. "TERT Expression in Pituitary Adenomas". (2017), 103-111.

APA	CAN N, Celik M, Yılmaz Bülbül B, Süt N, ÖZYILMAZ F, ayturk s, GÜLDİKEN S, SARIKAŞ N, ÖZ PUYAN F, YALTA T, KUTLU A (2017). TERT Expression in Pituitary Adenomas. Türk Patoloji Dergisi, 33(2), 103 - 111.
Chicago	CAN NURAY,Celik Mehmet,Yılmaz Bülbül Buket,Süt Necdet,ÖZYILMAZ Filiz,ayturk semra,GÜLDİKEN Sibel,SARIKAŞ Nurtaç,ÖZ PUYAN FULYA,YALTA Tülin Deniz,KUTLU ALİ KEMAL TERT Expression in Pituitary Adenomas. Türk Patoloji Dergisi 33, no.2 (2017): 103 - 111.
MLA	CAN NURAY,Celik Mehmet,Yılmaz Bülbül Buket,Süt Necdet,ÖZYILMAZ Filiz,ayturk semra,GÜLDİKEN Sibel,SARIKAŞ Nurtaç,ÖZ PUYAN FULYA,YALTA Tülin Deniz,KUTLU ALİ KEMAL TERT Expression in Pituitary Adenomas. Türk Patoloji Dergisi, vol.33, no.2, 2017, ss.103 - 111.
AMA	CAN N,Celik M,Yılmaz Bülbül B,Süt N,ÖZYILMAZ F,ayturk s,GÜLDİKEN S,SARIKAŞ N,ÖZ PUYAN F,YALTA T,KUTLU A TERT Expression in Pituitary Adenomas. Türk Patoloji Dergisi. 2017; 33(2): 103 - 111.
Vancouver	CAN N,Celik M,Yılmaz Bülbül B,Süt N,ÖZYILMAZ F,ayturk s,GÜLDİKEN S,SARIKAŞ N,ÖZ PUYAN F,YALTA T,KUTLU A TERT Expression in Pituitary Adenomas. Türk Patoloji Dergisi. 2017; 33(2): 103 - 111.
IEEE	CAN N,Celik M,Yılmaz Bülbül B,Süt N,ÖZYILMAZ F,ayturk s,GÜLDİKEN S,SARIKAŞ N,ÖZ PUYAN F,YALTA T,KUTLU A "TERT Expression in Pituitary Adenomas." Türk Patoloji Dergisi, 33, ss.103 - 111, 2017.
ISNAD	CAN, NURAY vd. "TERT Expression in Pituitary Adenomas". Türk Patoloji Dergisi 33/2 (2017), 103-111.